First patient dosed in Phase I trial of prostate cancer drug
The first patient has been dosed in the Phase I clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC).
ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy targets prostate-specific membrane antigen (PSMA) and, in preclinical studies, ART-101 exhibited higher tumour uptake and retention, as well as lower normal tissue and salivary gland uptake relative to current FDA-approved PSMA-targeting agents.
The Phase I trial is being conducted by radiopharmaceuticals company Archeus Technologies. Archeus is leading a first-in-human imaging study in mCRPC patients who are candidates to receive radioligand therapy with FDA-approved prostate cancer treatment Pluvicto. Participants will receive intravenous ART-101 – radiolabelled with the diagnostic isotope Indium-111 – to evaluate its safety, feasibility, biodistribution and kinetics, and tumour targeting.
“While current radioligand therapies provide a meaningful therapeutic benefit to patients with advanced prostate cancer, there are opportunities to even further enhance a patient’s quality of life and reduce even minimal side effects,” said Harshad Kulkarni, Chief Medical Advisor at BAMF Health and principal investigator of the study.
“This is especially important with upcoming alpha emitter-based therapies, where lower salivary gland uptake may help mitigate xerostomia.”
“With significant development support, and promising preclinical data, ART-101 is an innovative therapeutic candidate with the potential to address key limitations of currently available radiopharmaceutical therapies for patients with prostate cancer,” added Reinier Hernandez, Chief Technology Officer of Archeus Technologies and developer of the treatment.
“This clinical trial reflects Archeus’ foundational belief that precision imaging and dosimetry are essential to realising the full potential of radiopharmaceutical therapy, as well as our commitment to advancing the broader portfolio and platform we are building.”
Bruno Quinney, Content Team, DDW
